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Abstract
An important factor for successful translational stroke research is study quality. Low-
quality studies are at risk of biased results and effect overestimation, as has been intensely 
discussed for small animal stroke research. However, little is known about the methodological 
rigor and quality in large animal stroke models, which are becoming more frequently used in 
the field. 
Based on research in two databases, this systematic review surveys and analyses the 
methodological quality in large animal stroke research. Quality analysis was based on the 
Stroke Therapy Academic Industry Roundtable (STAIR) and the Animals in Research: 
Reporting In Vivo Experiments (ARRIVE) guidelines. Our analysis revealed that large animal 
models are utilized with similar shortcomings as small animal models. Moreover, translational 
benefits of large animal models may be limited due to lacking implementation of important 
quality criteria such as randomization, allocation concealment, and blinded assessment of 
outcome. On the other hand, an increase of study quality over time and a positive correlation 
between study quality and journal impact factor were identified. 
Based on the obtained findings, we derive recommendations for optimal study planning, 
conducting and data analysis/reporting when using large animal stroke models to fully benefit 
from the translational advantages offered by these models.
Key words: large animal, stroke, preclinical research, study quality, study validity
Page 2 of 35Journal of Cerebral Blood Flow and Metabolism
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
3
1. Introduction
Acute ischemic stroke management and care have profoundly improved with the 
introduction of intravenous thrombolysis and, recently, mechanical thrombectomy for large 
vessel occlusions.1 However, by far not all patients can benefit from the therapeutic progress 
due to numerous contraindications, restricted availability and therapeutic time windows of these 
therapeutic approaches. This causes a tremendous need for novel treatment options, but the 
translation of preclinical findings into clinically applicable and efficient therapies has so far 
been mostly ineffective and prone to failure.2
Critical assessment of rodent studies revealed that one important reason for the 
translational failure is the lack of methodological quality in these preclinical studies, causing a 
higher risk for poor internal validity, overestimation of effect sizes, and biased conclusions thus 
affecting rationale and design of subsequent clinical trials.3,4,5
Large animal models become more frequently used in preclinical stroke research since 
they are believed to provide a number of significant advantages in the translational process.6,7 
On the other hand, large animal stroke models are both more laborious and more expensive to 
utilize than rodent models. Budgetary limitations often restrict sample sizes in large animal 
experiments, which limits statistical power.8 Hence, it is essential to conduct large animal 
experiments with highest methodological rigor and to predefine precise endpoints that can be 
assessed with sufficient statistical power to take full advantage of the translational value of 
large animal stroke models.  
Little is known about the methodological rigor and quality of large animal stroke 
experiments. We performed a systematic review and quality assessment of studies using large 
animal stroke models. Our quality analysis was based on the Stroke Therapy Academic Industry 
Roundtable (STAIR)9,10 and Animals in Research: Reporting In Vivo Experiments (ARRIVE) 
guidelines.11 Based on the obtained results, we also provide suggestions for methodological 
improvements in large animal stroke research.
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2. Material & Methods
2.1. Study selection
         Literature research was performed by the first author (L.K.). L.K. was supported by E.M., 
a professional librarian with extensive experience in systematic literature research who helped 
with designing the search strategy. The two last authors (S.M. and J.B.) were consulted by L.K. 
in case of any doubts or questions when extracting information from the literature. Intra-
assessor reproducibility was not assessed.
2.1.1. Search strategy
We conducted a systematic search for preclinical large animal experiments in stroke using 
the Medline via Ovid from Wolters Kluwer and Science Citation Index Expanded via Web of 
Science from Clarivate Analytics data bases. 
The initial search was conducted on September 26th, 2017, and an update was performed 
on August 9th, 2019. Data base entries between January 1st, 1990 and August 8th, 2019 were 
covered.
Search terms were “large animal” (including any relevant species, e.g. dogs, cats, pigs, 
rabbits, non-human-primates, sheep, goats, etc.) and “ischemic stroke” (involving for instance 
“brain ischemia” OR “ischemic neuronal injury” OR “thrombembolic stroke” OR 
“cerebrovascular disorders”). In the search strategies we combined the aspects large aninals 
and ischemic stroke with AND. Within each aspect we generally combined keywords, their 
synonyms and – for indexed citations of MEDLINE – controlled for vocabulary terms (Medical 
Subject Headings) using the operator OR. Detailed search strategies are provided in 
Supplementary Tables 1 and 2. The search process was conducted and results were recorded 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (Figure 1A).
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2.1.2. Inclusion and exclusion criteria 
We included preclinical large animal studies conducted and published between 1990 and 
2019 that report investigations of therapeutic and/or diagnostic procedures for ischemic stroke. 
The studies needed to compare at least two groups, i.e. one in which a new procedure 
(therapeutic or diagnostic) is tested by comparing it to a second group being subjected to a 
standard or reference procedure (“control group”). Only studies in English were included.
We excluded studies focusing on diseases other than ischemic stroke, using small animal 
(e.g., rodent) models, clinical trials, in vitro studies, reviews, and meta-analyses. Purely 
descriptive studies only reporting a method or procedure, or non-controlled experiments (e.g., 
cases series) were also excluded. 
2.2. Data extraction
2.2.1.Basic study characteristics and impact factor 
First, study meta-data were extracted. Those included information on species, type of 
intervention, year of publication and region of origin (North America, Europe, Asia & Oceania), 
aim of evaluation (e.g., safety, feasibility), the stroke model used, study duration and 
information on investigation of dose-response-relationship (if applicable), compliance with 
animal welfare regulations, subject health condition prior to enrolment, animal housing 
conditions, and additional veterinary care.
Second, we documented the impact factor (IF) of the journal in which the study results 
were published, measured in the year of publication. IFs were identified via the annual 
Thomson Reuters Journal Impact Factor report. Where the IF could not be retrieved for the 
required year, we contacted the respective journal and asked to provide the IF for the particular 
year(s).
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2.2.2. Group sizes
We further extracted the number of subjects in experimental groups for each species. 
Group sizes were obtained for control and the diagnostic or therapeutic procedure group(s). 
2.3. Analysis
2.3.1. Assessment of Reporting Quality
We designated a scale that was applicable to both, diagnostic and therapeutic procedures, 
to assess study quality (Table 1). The quality score includes central STAIR and ARRIVE 
criteria, supplemented by additional quality items. The score comprised four categories, 
containing 6 items each. Category 1 addresses reporting of study subject details and welfare, 
category 2 covered the reporting of details on study design, category 3 addressed internal study 
validity, and category 4 assessed quality of outcome analysis and reporting. Each study was 
assigned a score from 0 (lowest quality) to 24 (highest quality), with each category having a 
quality value of 0 (lowest quality) to 6 (highest quality).
[Table 1 about here]
2.3.2. Additional aspects influencing study quality 
We further investigated whether study quality improved after the implementation of the 
STAIR guidelines in 1999, and their update in 2009.9,10 We also analyzed differences in quality 
with respect to species, region of study origin, and type of investigation (i.e., assessment of 
neuroprotectives, thrombolytics, cell therapies, diagnostics, and others). Furthermore, we 
evaluated possible associations between the quality score and IF. 
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2.3.3. Group sizes
Where a study reported more than one procedure group, they were all counted 
individually (maximum number was n=10). Average group sizes were calculated for control 
and procedure groups(s) for each species. We compared total group size (control plus procedure 
groups) across species as well as control and procedure groups separately.
2.4 Statistics 
All statistical analyses were performed using GraphPad PRISM 5 Software. Statistical 
significance was determined as p<0.05. Statistical significance was indicated with a single 
asterisk (*) at p<0.05, or a double asterisk (**) at p<0.01, respectively. Median as well as IQR 
(interquartile range including 25% and 75% quartiles) were documented. Comparisons between 
two groups were performed using the Wilcoxon signed rank test for non-parametric data to 
conservatively account for relatively small sample sizes. In case more than two groups were 
compared, the Kruskal-Wallis test was used, followed by Dunn`s correction for multiple 
comparisons. Spearman’s correlation analysis was performed to evaluate associations between 
quality score and IF. Group sizes were analyzed by ANOVA on ranks (no normal distribution 
of data) followed by Dunn's multiple comparison test.
3. Results 
3.1. Data set and year of publication
Initial and update searches identified a total of 10282 manuscripts being reduced to 8093 
after elimination of duplicates. (Figure 1A; a list of all studies included can be found in the 
supplementary material). A total of 208 studies were included in final analysis after screening 
abstracts and full text according to preset inclusion and exclusion criteria (Figure 1A). Results 
of basic study characteristics are shown in Table 2.
Analysis of publication output per year revealed that the number of large animal 
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experiments published from 1990 to 2014 generally decreased from n=56 in 1990-1994 to n=21 
in 2010-2014 (Figure 1B). However, there was a steep increase in published studies from 2015, 
reaching an all-time high (n=40) even though studies published in late 2019 are not yet included 
in our search strategy. This might be related to the milestone evidence for clinical benefit 
publication of mechanical thrombectomy in large vessel occlusion stroke by the publication of 
five randomized controlled trials in 2015 that may have sparked new interest in the field and an 
increased demand or large animal models to investigate related procedures.12,13
[Figure 1 about here]
[Table 2 about here]
3.2. Study Quality
The overall median quality score was 11 (range 3 to 22; IQR: 4 (9-13)) out of 24. The 
median quality score in the first category (reporting of study subject details and welfare) was 2 
out of 6 (range 1 to 5; IQR: 1 (1-2)). The second category (study planning quality) also reached 
a median quality score of 2 (range 1 to 6; IQR: 1 (2-3)). The third category (study conductance 
quality) had a median score of 3 (range 0 to 6; IQR: 2 (2-4)). Category 4 (result reporting and 
analysis quality) had a median quality score of 4 (range 0 to 6; IQR: 1 (2-4)). A significantly 
lower number of quality criteria were fulfilled in category 1 in comparison to the others 
(p<0.05).
3.2.1. Study subject details and welfare (category 1)
All studies reported the species used, but only 146 studies (70.2%) reported that the study 
was approved by responsible animal welfare authorities. Sex and age were reported by 31 
studies (15.0%). Sex only was reported by 153 (73.6%), while age was not reported solely. The 
pre-study health status was reported by only 12 studies (5.8%). Medication details including 
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the use of companion medication (e.g., analgetics, antibiotics) was reported in only 20 studies 
(9.6%). Comorbidities were not reported by any study.
3.2.2.Study planning (category 2)
Working hypotheses were reported in 207 (99.5%) studies. However, primary study 
endpoints were nominally determined in only 10 studies (4.8%). 135 (64.6%) studies reported 
that the study rationale was based on earlier small animal (n=79; 38.0%) or in vitro studies 
(n=25; 12.1%), or both (n=16; 7.7%). Effect size estimation and a priori sample size calculation 
can be performed based on such data. However, only 27 studies (13.0%) actually reported an 
estimation of effect size and a priori sample size calculation. A specific primary working 
hypothesis explicitly referring to previous in vitro and/or in vivo studies was reported in 18 
studies (8.7%). Inclusion and exclusion criteria were reported in 104 studies (50.0%), but only 
2 studies (1.0%) determined these criteria a priori.
3.2.3.Study conductance (category 3) 
Randomization was reported in 116 studies (55.8%), and allocation concealment was 
reported in 59 cases (28.4%). 104 studies (50.0%) reported blinded outcome assessment. 
Measurement of physiological parameters was reported in 165 cases (79.3%). The most 
frequently monitored parameters included mean arterial pressure (systemic), temperature, 
blood gases, blood pH, and exhalation gases. 186 studies reported appropriate outcome analysis 
modalities (89.4%; information on inappropriate analysis modalities are provided in 
Supplementary Table 3). These included survival rate (n=2; 1.0 %), functional outcome (n=67; 
32.2%), infarct size (n=46; 22.1%, as determined by appropriate methods such as imaging or 
histology), other imaging (n=90; 43.3%) or histology (n=61; 29.3%) endpoints, clinical 
chemistry (n=52; 25.0%), general pathology (n=24; 11.5%) or both (n=18; 8.7%). Only a 
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fraction of studies that recorded physiological parameters finally analyzed those (n=52; 25.0%). 
100 studies (48.1%) reported verification of infarct induction during intervention.
3.2.4.Result reporting and analysis (category 4)
168 studies (80.8%) adequately reported relevant data and findings in form of detailed 
tables or graphs. However, data were almost exclusively reported as means or medians. 
Individual data points were only provided by 16 studies (7.7%). Drop outs and excluded 
subjects were reported in 105 studies (50.5%). Application of appropriate statistical tests was 
reported in 192 studies (92.3%). 16 studies incompletely reported statistical analysis and, for 
example lacking information regarding statistical tests applied including post hoc tests. 91 
studies (43.8%) described potential sources of error and bias in the experiment, while 115 
(55.3%) reported limitations such as small sample size or that it was impossible to perform 
randomization. A conclusion fully justified by study findings was given in by most, but not all 
reports (n=190; 91.3%).
3.3. Additional influences on study quality
3.3.1. Study quality versus origin, species and type of intervention
Total median quality score was highest in studies from North America (Median: 12; IQR: 
10-14), statistically different from studies conducted in Asia & Oceania (Median: 10; IQR: 
(8.75-12) or  Europe (Median: 10; IQR: 8-11.75; p=0.0011 Figure 2A). Analysis of individual 
quality categories revealed no differences in category 1 (Figure 2B) but North American studies 
had statistically significantly higher scores in quality categories 2 (Median: 2.5; IQR: 2-3) and 
3 (Median: 4; IQR: 3-5) than their European counterparts (Median: 2; IQR: 1-2; p<0.01; Figure 
2C). Furthermore, North American studies were superior to Asian & Oceanian studies in 
category 3 (Median 3; IQR: 2-4; p<0.01; Figure 2D). We did not find statistically significant 
differences regarding category 4 (Figure 2E). Quality scores were neither influenced by species 
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used (Figure 2F) nor by the types of intervention (Figure 2G). Overall differences in median 
quality score in species varied significantly without any specific intergroup difference. 
[Figure 2 about here]
3.3.2. Study quality in the post-STAIR era
Methodological quality significantly improved after introduction of the STAIR guidelines in 
1999 (1990-1999 pre-STAIR median: 10, IQR: 8-12; post-STAIR median: 12, IQR: 9-15; 
p<0.01; Figure 2H). We also compared quality scores of studies published prior to the first 
STAIR guidelines to quality scores of studies published in the time between the first STAIR 
guideline publication and the 2009 update (2000-2009; median: 11; IQR: 9-13), and to scores 
of studies published after the STAIR 2009 update (2010-2019; median: 13.; IQR: 10-15). 
Quality scores of studies published after the STAIR 2009 update were higher than those of 
studies published before the initial STAIR guideline publication (1990-1999; p<0.01). They 
were also higher than quality scores of studies published after the first publication of STAIR 
guidelines and prior to the 2009 update (2000-2009; p<0.05; Figure 2I).
Improvements were particularly evident in categories 1 and 4.  In category 1, quality 
scores were lower in pre-STAIR studies (1990-1999; median: 1, IQR: 1-2) as compared to 
studies published after the first publication of STAIR guidelines and prior to the 2009 update   
(2000-2009; median: 2; IQR: 1.25-2) and to studies published after the 2009 update (2010-
2019; median: 2; IQR: 2-3; p<0.01). There was also a significant difference in category 1 
quality scores of studies published after the 2009 update to studies published between 2000 and 
2009 (p<0.01).  In category 4, quality scores of studies published after the 2009 STAIR update 
(2010-2019; median: 4; IQR: 3-5) were higher than those of studies published before the STAIR 
guidelines introduction (1990-1999; median: 3; IQR: 2-4) and those of studies published 
between 2000 and 2009 (median 3; IQR: 2-4; p<0.01 each). 
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3.3.3. Study quality versus impact factor
The IF was available for 172 studies (82.7%). We could not retrieve the IF for the 
remaining studies or no IF yet assigned on the particular journal in the year of publication 
(n=36; 17.3%). These latter studies were therefore excluded from the following analyses. 
Median IF was 3.3 (range 0.1 to 41.6; IQR: 2-4.6). Correlation analysis showed a statistically 
significant positive relationship between the total quality score and the IF (r=0.2802; p<0.01, 
alpha=0.05; Figure 3). We also correlated each quality score category with the IF and found 
that quality scores in all individual categories positively correlated with the IF (category 1: 
r=0.1851; p<0.05; category 2: r=0.1653; p<0.05; category 3:  r=0.1858; p<0.05; category 4: 
r=0.2297; p<0.01; Supplementary Figure 1). 
Figure 3 about here
3.3.4. Group sizes
Average group sizes across species are given in Table 3. Analysis of group sizes 
revealed that total (combined control and procedure) group size was largest in rabbits as 
compared to pigs (p<0.01), sheep and primates (p<0.05 each). Total group sizes in cats were 
larger than those in sheep (p<0.05; Figure 4A). Accordingly, control groups were largest in 
rabbits as compared to pigs (p<0.05) and primates (p<0.01; Figure 4B), while procedure groups 
were largest in rabbits as compared to pigs (p<0.01; Figure 4C).    
[Table 3 about here]
[Figure 4 about here]
4. Discussion
Systematic bias may cause over- or underestimation of study results.3 Quality items such 
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as randomization, allocation concealment, and blinded assessment improve internal validity 14, 
but are often neglected in small animal studies.3, 15, 16
Large animal models are believed to offer significant benefits for translational stroke 
research. They have  higher anatomical similarity to the human brain17 and to the 
cerebrovascular system.6, 7, 18 Another benefit is the potential to use these models in experiments 
closely mimicking a human clinical situation, and applying the same medical techniques and 
equipment for diagnostic and therapeutic interventions that would be used in human patients.7, 
19 Moreover, physiological characteristics of large animal models including heart and 
respiratory frequency, blood pressure as well as pharmacodynamic and pharmacokinetic 
profiles are similar to humans.20, 21 However, in view of these advantages, large animal studies 
require much greater efforts and resources. It is therefore important that quality in large animal 
studies is as high as possible to efficiently utilize the advantages large animal models offer for 
translational research.
Overall, we found that methodological quality in large animal stroke studies was 
mediocre. Although quality generally improved significantly over the last decades and 
potentially due to the 1999 publication and 2019 update of the STAIR criteria, our analysis 
revealed some important shortcomings. Improvements are needed in reporting study subject 
details and welfare (quality score category 1). Aspects such as sex and age, pre-study health 
conditions, and medications should be reported routinely for optimal study transparency and 
reproducibility, and transferability of study results.9 The lack of comorbid large animal models 
is not surprising. Comorbidities are difficult to simulate in outbred large animal models as they 
occur due to age, distress, malnutrition and other factors according to the human situation, and 
can take significant time in large animals to develop. Research on models exhibiting 
comorbidities may remain a domain of small animal research. Nevertheless, any spontaneously 
occurring comorbidities being diagnosed in large animals used for research should be reported.
Working hypotheses were reported in almost all studies (99.5%), but often without any 
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obvious influence on study design. For instance, only 4.8% of the studies defined and reported 
primary endpoints, while analysis of expectable effect size and a priori sample size calculation 
were performed in few cases only (13.0%). This may severely limit the translational benefits 
of large animal models since study results may be hard to interpret based on potentially poor 
statistical power. Given the significant resources required to perform large animal studies, 
considering these aspects is essential. On the other hand, determination of effect size can be 
challenging when previous research data is lacking or not entirely applicable. In these cases, 
we recommend to perform large animal pilot studies that may help to assess basic 
characteristics in the respective model, such as variability of infarct size and its impact on the 
envisioned primary endpoint.
While half of the studies reported inclusion and exclusion criteria (50.0%), almost none 
(1.0%) applied them a priori. Defining inclusion and exclusion criteria during or after the study 
is believed to be a major source of bias, particularly when a study is conducted in non-blinded 
fashion. Hence, such bias can unfortunately not be excluded for most studies we analyzed. 
Important quality aspects such as randomization (55.8%), allocation concealment 
(28.4%), and blinded assessment of outcome (50.0%) were more frequently reported in large 
animal studies as compared to small animal stroke experiments (randomization: 33.3%; blinded 
assessment of outcome: 44.4%,16 allocation concealment: 25.9%; randomization, allocation 
concealment and blinded assessment of outcome: 24.1.%.22 Nevertheless, the number of studies 
not reporting those is still remarkably high in particular since blinding and randomization 
should be minimum standard quality assurance procedures in confirmative stroke research23 to 
which almost all large animal studies aim to contribute.
 Imaging techniques such as magnetic resonance imaging, computed tomography, and 
angiography (43.5%) as well as physiological monitoring (80.4%) were utilized relatively 
frequently. This is a positive aspect since large animals are particularly suitable for clinical 
imaging techniques while thorough physiological monitoring creates meaningful information 
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that may warrant subject in- or exclusion. However, verification of infarct induction (only 
reported in 48.1%) as well as infarct size should be conducted thoroughly and routinely to avoid 
the risk of increasing inter-subject/-study/-group variability, further reducing statistical power 
of an experiment. Parameters such as cerebral blood flow reduction for verification of infarct 
induction was documented by only 7.2% of studies. This is surprising since these parameters 
are relatively easy to determine in large animals, while clinical imaging techniques may be used 
to confirm the induced lesion directly.21
Large animals are suitable for long-term studies including functional endpoint 
assessment. However, we only found a relatively low percentage (6.7%) of studies being 
conducted for more than one month, the minimum follow-up period recommended by the 
STAIR guidelines for functional endpoints. Next to costs, this may be due to the selection of 
other primary endpoints such as safety or efficacy of recanalization methods which can be 
assessed more rapidly. However, experimenters who wish to assess behavioral endpoints 
should take into consideration that functional consequences of stroke in large animals can be 
more heterogeneous than in rodent models, and may develop over longer time spans.24
We recognized significant improvements in methodological quality since the publication 
of the first STAIR guidelines in 1999, and in particular after the STAIR guideline update in 
2009. Comparable improvements were reported for small animal stroke studies from 2010 to 
2013.25 These findings indicate the positive impact of specific good research practice 
guidelines, which should be advanced continuously as evidenced by the recent 2019 STAIR 
guideline updates.26 In contrast to previous findings in small animal studies,27 we also identified 
positive association (r=0.2802; p<0.01) between study quality and publication in high-impact 
journals. In particular, total quality score as well as quality scores in all single categories 1-4 
significantly correlated with higher IF. This is an encouraging result since all these categories 
include items being important to prevent bias. These items are hence indispensable for a valid 
and transparent exchange of information between researchers. 
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          Group sizes were significantly larger in rabbits as compared to other species. This is not 
surprising as rabbits are the smallest and cheapest of all large animal species what allows for 
larger group sizes. Importantly, group sizes in primates are generally not different to that of 
other species. This does not mean that group sizes were sufficient for each research question, 
but shows that costs related to primate experiments did not prevent the same group sizes as seen 
in other large animal species despite rabbits.
Our study has a number of limitations. We applied a predefined search strategy and 
protocol being developed together an expert in literature meta-analyses (E.M.) and experts in 
stroke research (J.B., S.M.). However, search strategy and protocol were not registered (ex ante 
protocol). Data extraction was not done in duplicate, but senior experts were consulted in all 
doubtful cases. Intra-assessor reproducibility was not assessed. Moreover, we did not 
discriminate between studies focusing on therapeutic and diagnostic procedures. Large animal 
models provide a number of benefits over rodent models for diagnostic studies due to the larger 
brain size and in particular when clinical imaging is used.33 However, those studies are often 
exploratory in nature. Since quality demands are different (and a bit lower) than in confirmative 
studies, those imaging-related studies would perform normally worse but still can contribute 
invaluably to their respective field.34 Finally, we did not include a number of insightful imaging 
studies because they did not conduct a formal inter-group comparison.35,36,37,38
5. Conclusions and Recommendations
Although large animal models offer a offer a number of clear advantages for translational 
stroke, we found that they have similar shortcomings to small animal models, limiting this 
benefit. Therefore, we derived a number of recommendations to address these limitations but 
are, at the same time, relatively easy to implement.
5.1 Study planning and preparation
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Large animal stroke studies are mostly confirmative studies. Therefore, study planning 
should be based on high quality standards applied for randomized controlled clinical trials 
(RCTs) when possible. Key elements of RCT planning and design such as a priori sample size 
calculation and endpoint definition should be conducted.23 We encourage to involve 
statisticians already in early planning steps to optimize study design.28 Study planning can also 
be supported by specific software tools. For instance, the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research provides a freeware called Experimental 
Design Assistance (https://eda.nc3rs.org.uk), which is free to use and was built to guide 
researchers through their study planning.29 Since optimal sample sizes may not be achieved for 
all endpoints, it is important to clearly define the most appropriate primary study endpoint, and 
to power the study properly. Collaboration between research teams in form of peer quality 
checks and validation of study design can highly increase objectivity and validity of a study.30 
Inter-group collaboration and transfer of experience can also help to handle very complex 
models and/or experimental setups, helping to reduce inter-subject variability negatively 
affecting statistical power. Confirmative studies might be preregistered to maximize 
transparency.39 
5.2 Effect size estimation and pilot trials
Collecting valid information from previous research is essential for reliable effect size 
estimation. If such data are not available, pilot studies may be helpful for at least basically 
estimating variability of stroke impact and outcome in the model. In case previous experience 
with a particular model is low, variability is more likely to be higher and effect size is more 
likely to lower in such pilot trials.  This will contribute to more conservative study planning 
since sample sizes calculated based on that information will be higher.. An important side effect 
of pilot trials is experimenter training which limits experimenter-caused endpoint variability 
(see below) in the main experiment. In addition, meta-analyses can help to collect relevant 
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information on effect size or regarding a specific research question from related fields.31
5.3 Reducing the effect of sample size limitations and endpoint variability
Financial and logistical restrictions often impact sample and group sizes in large animal 
experiments. This is an understandable limitation which is difficult to overcome. Selection of 
a proper and relevant endpoint that can be adequately powered with respected to the addressed 
research question is therefore important to minimize the risk for low statistical power. Of note, 
some endpoints often used in studies assessing therapeutic interventions including infarct size 
and functional deficits, exhibit a higher variability in large animal models than in rodent. This 
makes comparison of absolute data more difficult.24 Relative analysis of repeatedly assessed 
endpoints, i.e. in comparison to the individual initial infarct size and/or functional deficit can 
efficiently compensate for such variability. Repeated assessments also allow calculating the 
area under the curve for particular endpoints. This may provide a benefit in statistical power to 
identify whether a real outcome benefit is present over time. However, this comes at the cost 
of temporal resolution: it cannot be concluded exactly when this benefit became evident. There 
is also preliminary evidence for fast and slow stroke progressors in large animals, indicating 
different collateral status and somewhat resembling the human situation, but further 
contributing to inter-subject variability. It is recommended to consider this fact when planning 
an acute stroke study.32
In experiments of highly similar design, controls may be pooled. Of note, this counteracts 
randomization and therefore requires extremely thorough validation of comparability of control 
subjects from different experiments/sources. If comparability is thoroughly proven, this may 
help to increase statistical power, but the limitations of this approach and potentially resulting 
bias need to be discussed transparently and in detail when publishing results. 
The possibility to repeatedly collect a broad spectrum of physiological data should be 
utilized where possible, as deviation from normal parameter ranges may explain variability and 
warrant post-hoc exclusion of subjects in single cases.
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5.4 Study duration and documentation
We recommend considering long-term experiments whenever meaningful and possible 
and meeting animal welfare requirements. Even though long-term experiments involve greater 
efforts, the amount of data collected for individual subjects may be much higher, providing a 
better overall picture on the assessed intervention. Documentation should be as transparent as 
possible because transparency is not challenging or laborious, but contributes significantly to 
increased scientific rigor, reproducibility, and unbiased study result interpretation. 
Methodological limitations including lacking quality aspects due to good reason should be 
clearly stated as this allows bet er interpretation of positive, neutral and negative study results. 
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Figure legends
Figure 1. Overview on quantitative search results and frequency of large animal 
experiments in stroke research since 1990.
(A) Flow diagram of publication identification. N = Number of publications. Records 
were excluded after screening title and abstracts. Full-text articles were then screened and 
excluded for a priori determined reasons. (B) Timeline of publication in large animal stroke 
research (1990-2019): The increase of large animal stroke studies in the last years is potentially 
due to the breakthrough in recanalization therapies, prompting a number of follow-on 
translational studies utilizing large animal stroke models.
Figure 2. Influence of study origin and STAIR criteria publication on study quality. 
(A) Total quality score, (B) Category 1: Reporting of study subject and animal welfare, 
(C) Category 2: Study planning quality (North America vs. Europe p<0.01), (D) Category 3: 
Study conductance quality (North America vs. Asia & Oceania p<0.01), (E) Category 4: Result 
reporting and analysis quality (North America vs. Europe p<0.01), (F) Influence of species, (G) 
Improvement in total methodological quality since the publication of the first STAIR criteria 
in 1999 (p<0.01), (H) Improvement in total methodological quality since the publication of the 
first STAIR criteria in 1999 comparing to their amendment in 2009 (2010-2019 vs. 1990-1999 
p<0.01, and 2010-2019 vs. 2000-2009 p<0.05),  (I) Influence of type of intervention. Horizontal 
lines and whiskers indicate the median with lower and upper 95% CI. *p<0.05; **p<0.01.
Figure 3. Association between total quality score versus impact factor.
Scatterplot shows correlation between quality score and IF (p<0.01). Number of included 
studies is 172, no IF could be retrieved for 36 studies. The latter studies were excluded from 
this analysis.
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Figure 4. Group sizes across species.
         (A) Total group sizes were largest in rabbits as compared to pigs (p<0.01), primates and 
sheep (p<0.05 each). (B) Control group sizes were larger in rabbits as compared to primates 
(p<0.01) and pigs (p<0.05). (C) Procedure group sizes were larger in rabbits as compared to 
pigs (p<0.01). Horizontal lines and whiskers indicate the median with lower and upper 95% CI. 
*p<0.05, **p<0.01.
Tables
Table 1. Quality score items. 
Category 1: Reporting of study subject 
details and welfare
Category 2: Study planning quality
Item Score point 
allocation
Item Score point 
allocation
1. Animal protocol 
approved
Reported 
yes=1/no=0
1. Study hypothesis Reported 
yes=1/no=0
2. Species Reported 
yes=1/no=0
2. A priori endpoint 
definition
Reported 
yes=1/no=0
3. Sex and Age Reported 
yes=1/no=0
3. A priori sample size 
calculation
Reported 
yes=1/no=0
4. Pre-Study Health Reported 
yes=1/no=0
4. Reference to previous 
studies
Reported 
yes=1/no=0
5. Comorbidities Reported 
yes=1/no=0
5. Inclusion/Exclusion 
criteria
Reported 
yes/no=0
6. Adequate 
medication
Reported 
yes=1/no=0
6. Effect size/Treatment 
effect
Reported 
yes=1/no=0
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Category 3: Internal study validity Category 4: Outcome analysis and 
reporting
Item Score point 
allocation
Item Score point 
allocation
1. Blinding Reported 
yes=1/no=0
1. Individual data points Reported
yes=1/no=0
2. Randomization Reported 
yes=1/no=0
2. Drop outs/Excluded 
subjects
Reported 
yes=1/no=0
3. Allocation 
concealment
Reported 
yes=1/no=0
3. Appropriate statistical 
tests
Used 
yes=1/no=0
4. Physiological 
parameters
Measuring reported 
yes=1/no=0
4. Potential error sources Reported 
yes=1/no=0
5. Analysis 
modalities
Appropriate 
modalities reported# 
yes=1/no=0
5. Study/Methodological 
limits
Reported 
yes=1/no=0
6. Infarct induction 
confirmation
Reported 
yes=1/no=0
6. Justified conclusion 
given##
Provided 
yes=1/no=0
#analysis modalities were considered appropriate when being sufficient to assess the 
respective research question or endpoint (see Supplementary Table 3 for details).
##conclusion was considered justified when supported by correctly analyzed results.
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Table 2. Basic Characteristics of included Animal Experimental Studies.
Item Frequency (%) Item Frequency (%) Item Frequency (%)
Species Type of intervention Study duration
Rabbit n=96 (46.1%) Neuroprotectives n=113 (54.3%) Acute phase (<24h) n=139 (66.9%)
Cat n=43 (20.7%) Thrombolytics n=52 (25.0%) 1-3 days n=26 (12.5%)
Dog n=16 (7.7%) Cell therapies n=7 (3.4%) <1 week n=15 (7.2%)
Non-Human-Primate n=32 (15.4%) Diagnostics n=15 (7.2%) <1month n=14 (6.7%)
Pig n=19 (9.1%) Others# n=21 (10.1%) >1 month n=14 (6.7%)
Non-Human-Primate & 
Rabbit
n=1 (0.5%)
Sheep n=1 (0.5%)
Region Primary endpoint Stroke model
North America n=134 (64.4%) Efficacy n=162 (77.9%) Transient n=120 (57.7%)
Europe n=24 (11.5%) Safety n=12 (5.8%) Permanent n=76 (36.5%)
Asia/Oceania n=50 (24.1%) Feasibility n=22 (10.5%) Transient +Permanent n=1 (0.5%)
Safety + n=1 (0.5%) Not reported n=11 (5.3%)
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Feasibility
Safety + Efficacy n=11 (5.3%)
Further information
Additional veterinary care 
reported 
n=11 (5.3%)
Dose-response 
relationship reported
n=30 (14.4%)
Compliance with animal 
welfare regulations 
reported 
n=128 (61.5%)
Pre-study quarantine 
reported
n=3 (1.4%)
Animal housing 
conditions## reported
n=23 (11.1%)
#these included hypothermia (n=7), hemodilution (n=5), facial nerve stimulation (n=2), hyperglycemia, retrograde transvenous perfusion, crosslinked 
hemoglobin transfusion, alkalinization of systemic pH, omental transposition, induced hypertension, RIPC (short term remote ischemic 
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postconditioning) (n=1 each)
##e.g., feeding, light/dark circle, single or grouped housing
Table 3. Median experimental group sizes across large animal species.
Non-human primate Rabbit Dog Cat Sheep Pig
C P T C P T C P T C P T C P T C P T
7.4
(1-24) 
n=35
6.3
(2-17) 
n=64
6.6 
(1-24) 
n=99
12.4 
(2-50) 
n=108
10.0 
(2-57) 
n=267
11.0 
(2-57) 
n=375
7.1 
(5-10) 
n=15
9.0
(1-16) 
n=25
8.3 
(1-16) 
n=40
8.7
(2-17) 
n=45
8.6 
(3-18) 
n=77
8.6 
(2-18) 
n=122
6 
(6) 
n=1
4.25 
(3-6) 
n=4
4.2 
(3-6) 
n=5
5.8
(2-11) 
n=16
6.4
(1-10) 
n=45
6.2 
(1-11) 
n=60
C: control group; P: procedure group(s); T: total (combined) groups. Ranges (min.-max.) are given in brackets. n describes numbers of groups 
throughout the included literature.
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Figure 1. Overview on quantitative search results and frequency of large animal experiments in stroke 
research since 1990. 
(A) Flow diagram of publication identification. N = Number of publications. Records were excluded after 
screening title and abstracts. Full-text articles were then screened and excluded for a priori determined 
reasons. (B) Timeline of publication in large animal stroke research (1990-2019): The increase of large 
animal stroke studies in the last years is potentially due to the breakthrough in recanalization therapies, 
prompting a number of follow-on translational studies utilizing large animal stroke models. 
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Figure 2. Influence of study origin and STAIR criteria publication on study quality. 
(A) Total quality score, (B) Category 1: Reporting of study subject and animal welfare, (C) Category 2: 
Study planning quality (North America vs. Europe p<0.01), (D) Category 3: Study conductance quality 
(North America vs. Asia & Oceania p<0.01), (E) Category 4: Result reporting and analysis quality (North 
America vs. Europe p<0.01), (F) Influence of species, (G) Improvement in total methodological quality since 
the publication of the first STAIR criteria in 1999 (p<0.01), (H) Improvement in total methodological quality 
since the publication of the first STAIR criteria in 1999 comparing to their amendment in 2009 (2010-2019 
vs. 1990-1999 p<0.01, and 2010-2019 vs. 2000-2009 p<0.05),  (I) Influence of type of intervention. 
Horizontal lines and whiskers indicate the median with lower and upper 95% CI. *p<0.05; **p<0.01. 
216x278mm (96 x 96 DPI) 
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Figure 3. Association between total quality score versus impact factor. 
Scatterplot shows correlation between quality score and IF (p<0.01). Number of included studies is 172, no 
IF could be retrieved for 36 studies. The latter studies were excluded from this analysis. 
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Figure 4. Group sizes across species. 
        (A) Total group sizes were largest in rabbits as compared to pigs (p<0.01), primates and sheep 
(p<0.05 each). (B) Control group sizes were larger in rabbits as compared to primates (p<0.01) and pigs 
(p<0.05). (C) Procedure group sizes were larger in rabbits as compared to pigs (p<0.01). Horizontal lines 
and whiskers indicate the median with lower and upper 95% CI. *p<0.05, **p<0.01. 
377x175mm (120 x 120 DPI) 
Page 35 of 35 Journal of Cerebral Blood Flow and Metabolism
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
